Alcami

FDA

CorMedix hit with another CRL in effort to get nod for DefenCath

The FDA has slapped troubled biotech CorMedix with its second complete response letter because of manufacturing issues with DefenCath.

Kevin Dunleavy Aug 9, 2022 10:00am

Sterling Pharma Solutions Cary NC

Sterling plots ADC specialist buyout in early 2021

Dec 2, 2020 10:07am

People shaking hands across a desk that has computer and papers on it

CDMO Sterling acquires former Alcami ingredients facility

Oct 1, 2020 9:39am

Alcami

Madison Dearborn Partners snatches up CDMO Alcami

Jun 4, 2018 2:06pm